The INCATE Selection Committee has chosen four new ventures for Stage I support. Meet the latest additions to the INCATE family:

Adina Technologies – This project aims to enhance infection control in prosthetic devices by introducing Adina NanoGuard® — an innovative technology that creates nature-inspired antimicrobial nanostructures on implant surfaces, thereby reducing the reliance on antibiotic treatments.

Alpioner Therapeutics – Developing the first KBMA prophylactic vaccine against Pseudomonas aeruginosa, to fight against AMR.

APY Therapeutics – APY Therapeutics, LLP is developing arylmyxopyronins–APYs–as novel first-in-class oral treatments for lower-respiratory-tract infections and skin-and-soft-tissue infections by Gram-positive and fastidious Gram-negative bacteria, including drug-resistant, multi-drug-resistant, and pan-drug-resistant isolates.

Baxiva – Preventing tough infections with next-generation glycoconjugate vaccines.

Learn more about all the Stage I ventures selected in previous sessions HERE.